Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zydus Lifesciences Limited

https://www.zyduslife.com/index

Latest From Zydus Lifesciences Limited

Watch Out Pfizer, Moderna - India’s First mRNA Vaccine Is Here

With India’s first and the world’s third mRNA vaccine, Gennova plans to provide access to its COVID-19 vaccine to those deprived of doses from Pfizer and Moderna. HDT Bio Corp’s suit in the US is not seen impacting marketing plans in India, COO tells Scrip

Commercial Coronavirus COVID-19

COVID-19 Vaccine Pediatric Landscape In India - Biological E Scores, Zydus At Zero

India’s COVID-19 immunization focus has shifted to children as over 88% adults are fully vaccinated. However, Scrip’s examination of weekly data reveals the number of doses given to children are also dropping sharply off peaks. Meanwhile, Biological E is winning over others like Novavax in this segment while Zydus Lifesciences is yet to score

Commercial Coronavirus COVID-19

Strides Founder Back As MD, Asserts Confidence In US As Company Exits Parts Of Europe

Back as Strides managing director, founder Arun Kumar is confident of reversing a slide in profits via a recalibration strategy that saw the company exit Canada and a few European markets. Meanwhile, eyes are on the fallout of a CRO that serviced Strides apart from Sandoz, Teva and more getting caught in CHMP and FDA’s crosshairs.

Strategy Sales & Earnings

Strides Founder Back As MD, Asserts Confidence In US As Company Exits Parts Of Europe

Back as Strides managing director, founder Arun Kumar is confident of reversing a slide in profits via a recalibration strategy that saw the company exit Canada and a few European markets. Meanwhile, eyes are on the fallout of a CRO that serviced Strides apart from Sandoz, Teva and more getting caught in CHMP and FDA’s crosshairs

Commercial Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Cadila Healthcare
    • Zydus Pharmaceuticals USA
    • German Remedies
    • Zynesher Pharmaceuticals USA LLC
    • Nesher Pharmaceuticals Inc
    • Quimica e Farmaceutica Nikkho do Brasil Ltda
    • Bremer Pharma GmbH
    • Nippon Universal Pharmaceuticals
    • Zydus Discovery DMCC
    • Zydus Urosciences
    • Sentynl Therapeutics, Inc
    • Zydus Lifesciences Ltd
    • Cadila Healthcare Ltd.
    • Zydus Cadila
UsernamePublicRestriction

Register